Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 3.00 (0.997%)
Open: 306.00
High: 309.00
Low: 300.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Form for notification of major holdings

3 Jul 2019 07:00

RNS Number : 3211E
Hutchison China Meditech Limited
03 July 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Prudential plc group of companies

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

28/06/2019

6. Date on which issuer notified (DD/MM/YYYY):

01/07/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.10%

0.00%

5.10%

666,577,450

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD USD0.10

KYG4672N1198

10,899,950

1.63%

SPON ADS

US44842L1035

23,141,235

3.47%

SUBTOTAL 8. A

34,041,185

5.10%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Prudential plc

(Parent Company)

5.10%

0.00%

5.10%

M&G Prudential Limited (wholly owned subsidiary of Prudential plc)

5.10%

0.00%

5.10%

M&G Group Limited

(wholly owned subsidiary of Prudential plc)

5.10%

0.00%

5.10%

M&G Limited

(wholly owned subsidiary of M&G Group Limited)

5.10%

0.00%

5.10%

M&G Investment

Management Limited

(wholly owned subsidiary of M&G Limited)

5.10%

0.00%

5.10%

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

 

 

Place of completion

London, United Kingdom

Date of completion

01 July 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLDMGGNKFLGLZG
Date   Source Headline
21st Apr 20229:30 amRNSVesting of awards under Long Term Incentive Plan
31st Mar 20227:00 amRNSUpdate on Status under HFCAA
23rd Mar 20228:30 amRNS2021 Annual Report and Notice of AGM
11th Mar 20229:00 amRNSUpdate on Status under HFCAA
9th Mar 20228:30 amRNSVesting of awards under Long Term Incentive Plan
7th Mar 20227:00 amRNSHUTCHMED Receives $15m Milestone from AstraZeneca
3rd Mar 20223:30 pmRNSPublication of Form 20-F
3rd Mar 202212:30 pmRNSRetirement of CEO and appointment of new CEO
3rd Mar 202212:00 pmRNSFull Year Results and Business Updates
1st Mar 20228:30 amRNSApproval to Commercialize ELUNATE® in Macau
7th Feb 20228:30 amRNSHUTCHMED to Announce 2021 Final Results
4th Feb 20229:30 amRNSPhase Ib/II Combination Study of HMPL-453
20th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-653
19th Jan 20227:00 amRNSHUTCHMED Data at ASCO GI Cancers Symposium
17th Jan 20229:00 amRNSHolding(s) in Company
12th Jan 202211:00 amRNSBreakthrough Therapy Designation for HMPL-523
10th Jan 20227:00 amRNSHUTCHMED Initiates Phase I Study of HMPL-760
31st Dec 20217:00 amRNSBlocklisting Six Monthly Return
31st Dec 20217:00 amRNSTotal Voting Rights
20th Dec 20217:00 amRNSHUTCHMED Included in FTSE Russell Indexes
15th Dec 20219:45 amRNSGrant of Share Options and Awards under LTIP
14th Dec 20217:00 amRNSHMPL-523 Clinical Data Presented at ASH
10th Dec 202110:00 amRNSHUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
6th Dec 20217:00 amRNSHUTCHMED Completes Planned Enrollment of FRESCO-2
3rd Dec 20217:00 amRNSUpdated NRDL to include ELUNATE and SULANDA
30th Nov 20218:30 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSHUTCHMED and AZ Initiate SACHI Phase 3 Trial
8th Nov 20217:00 amRNSHUTCHMED to Present Clinical Data at ASH
1st Nov 20217:00 amRNSHUTCHMED and AZ Initiate SAMETA Global P3 Trial
29th Oct 20219:30 amRNSTotal Voting Rights
28th Oct 20217:00 amRNSHUTCHMED Initiates Phase III Trial of HMPL-523
20th Oct 20219:30 amRNSGrant of Awards under Long Term Incentive Plan
30th Sep 20219:30 amRNSTotal Voting Rights
29th Sep 20217:00 amRNSClosure of Non-Core OTC Joint Venture Divestment
29th Sep 20217:00 amRNSHUTCHMED Highlights Presentations at CSCO 2021
21st Sep 20217:00 amRNSHUTCHMED Initiates Phase III Trial SURTORI-01
20th Sep 20217:00 amRNSJapan Bridging Study For Surufatinib Initiated
13th Sep 20217:00 amRNSBreakthrough Therapy Designation for Amdizalisib
8th Sep 202111:30 amRNSHUTCHMED and AZ Initiate Phase III Trial in China
7th Sep 20219:30 amRNSHUTCHMED to Present Clinical Data at ESMO
2nd Sep 202112:45 pmRNSGrant of Share Options, and Awards under LTIP
31st Aug 20219:30 amRNSTotal Voting Rights
26th Aug 20217:00 amRNSPhase Ib/II Trial of Fruquintinib & Tislelizumab
23rd Aug 20217:00 amRNSHUTCHMED Selected for Certain Hang Seng Indexes
17th Aug 20219:30 amRNSELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
9th Aug 20217:00 amRNSHUTCHMED & Epizyme Announce TAZVERIK Collaboration
30th Jul 20219:30 amRNSTotal Voting Rights
28th Jul 202112:00 pmRNSInterim Results and Business Updates
28th Jul 20217:00 amRNSPhase II Trial of ORPATHYS Initiated
23rd Jul 202112:01 pmRNSStabilizing Actions & End of Stabilization Period

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.